Abstract
BackgroundFocal inflammatory disease activity in relapsing-remitting multiple sclerosis (RRMS) diminishes with increasing age. Here we use patient-level data from randomised controlled trials (RCTs) of natalizumab treatment in RRMS to investigate...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have